E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
B-cell malignancies |
neoplasias malignas de linfocitos B |
|
E.1.1.1 | Medical condition in easily understood language |
blood cancer in the lymph nodes |
cáncer de sangre en los ganglios linfáticos |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003901 |
E.1.2 | Term | B-cell lymphoma NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the long-term safety of zanubrutinib, as monotherapy or in combination, in patients with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib |
• Evaluar la seguridad a largo plazo de zanubrutinib, en monoterapia o en terapia combinada, en pacientes con neoplasias malignas de linfocitos B que participaron en un estudio principal de BeiGene para zanubrutinib |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the long-term efficacy of zanubrutinib, as monotherapy or in combination, by measuring the following: - Progression-free survival (PFS) - Duration of response (DOR) - Overall survival (OS) |
• Evaluar la eficacia a largo plazo de zanubrutinib, en monoterapia o en terapia combinada, mediante la medición de lo siguiente: o Supervivencia sin progresión (SSP) o Duración de la respuesta (DR) o Supervivencia general (SG) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. As part of a BeiGene parent study: a. Currently participating, or b. Participated recently
2. Intent to continue or start zanubrutinib treatment after occurrence of any of the following: a. At time of final analysis or study closure of the eligible BeiGene parent study: •For zanubrutinib-naive patients, rationale for initiation of zanubrutinib treatment must be discussed with and approved by the medical monitor b. At time of progressive disease (PD) after occurrence of either of the following: i Patient was receiving zanubrutinib at the time of progressive disease (PD), and the investigator and patient agree it is in the patient’s best interest to continue zanubrutinib (discussion with and approval by the medical monitors of the parent study and this study required) ii Patient was receiving a non-BTK inhibitor drug at the time of progressive disease (PD), and the investigator and patient agree that the patient may clinically benefit from zanubrutinib treatment (discussion with and approval by the medical monitors of the parent study and this study required) c. At an alternative timepoint for an alternative reason (discussion with and approval by the medical monitor required)
3. Patient who is currently on zanubrutinib treatment: Does not meet any criteria for zanubrutinib hold or permanent discontinuation, and, in the opinion of the investigator, will continue to benefit from zanubrutinib treatment |
1. Como parte de un estudio de padres de BeiGene: a. Participando actualmente, o B. Participó recientemente
2. Tiene la intención de continuar o comenzar el tratamiento con zanubrutinib después de que ocurra cualquiera de los siguientes: a. En el momento del análisis final o cierre del estudio del estudio principal elegible de BeiGene: • Para los pacientes que no han recibido zanubrutinib, el monitor médico debe discutir y aprobar el inicio del tratamiento con zanubrutinib. b. En el momento de la enfermedad progresiva (EP) después de la aparición de cualquiera de los siguientes: i El paciente estaba recibiendo zanubrutinib en el momento de la enfermedad progresiva (EP), y el investigador y el paciente están de acuerdo en que lo mejor para el paciente es continuar con zanubrutinib (discusión y aprobación de los monitores médicos del estudio principal y este estudio requerido) ii El paciente estaba recibiendo un fármaco no inhibidor de BTK en el momento de la enfermedad progresiva (EP), y el investigador y el paciente están de acuerdo en que el paciente puede beneficiarse clínicamente del tratamiento con zanubrutinib (discusión y aprobación de los monitores médicos del estudio principal y este estudio requerido) C. En un momento alternativo por un motivo alternativo (se requiere la discusión y la aprobación del monitor médico)
3. Paciente que está actualmente en tratamiento con zanubrutinib: No cumple con ningún criterio de suspensión o suspensión permanente de zanubrutinib y, en opinión del investigador, seguirá beneficiándose del tratamiento con zanubrutinib. |
|
E.4 | Principal exclusion criteria |
1. Permanently discontinued from zanubrutinib treatment in the BeiGene parent study due to unacceptable toxicity, noncompliance with study procedures, or withdrawal of consent 2. Uncontrolled active systemic infection or recent infection requiring parenteral anti-microbial therapy 3. Life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of zanubrutinib, or put the study outcomes at undue risk 4. Concomitant chemotherapy, targeted therapy, radiation therapy, antibody-based therapy, or any prohibited concomitant therapy outlined in the protocol 5. Pregnant or lactating woman 6. Inability to comply with study procedures 7. Concurrent participation in another therapeutic clinical study 8. History of progressive disease (PD) while receiving a BTK inhibitor (excluding zanubrutinib) |
1. Se interrumpió permanentemente el tratamiento con zanubrutinib en el estudio original de BeiGene debido a toxicidad inaceptable, incumplimiento de los procedimientos del estudio o retiro del consentimiento. 2. Infección sistémica activa no controlada o infección reciente que requiera tratamiento antimicrobiano parenteral 3. Enfermedad potencialmente mortal, afección médica o disfunción del sistema de órganos que, en opinión del investigador, podría comprometer la seguridad del paciente, interferir con la absorción o el metabolismo de zanubrutinib o poner los resultados del estudio en un riesgo indebido. 4. Quimioterapia concomitante, terapia dirigida, radioterapia, terapia basada en anticuerpos o cualquier terapia concomitante prohibida descrita en el protocolo. 5. Mujer embarazada o lactante 6. Incapacidad para cumplir con los procedimientos del estudio 7. Participación concurrente en otro estudio clínico terapéutico 8. Antecedentes de enfermedad progresiva (EP) mientras recibía un inhibidor de BTK (excepto zanubrutinib) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the study is safety as assessed by incidence of all TEAEs and SAEs. |
• El criterio de valoración principal del estudio es la seguridad evaluada por la incidencia de todos los AA y AAG que surjan durante el tratamiento. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
on or after the first dose of study drug up to 30 days after the last dose of study drug or initiation of new antineoplastic therapy, whichever comes first |
durante o tras la primera dosis del fármaco del estudio y hasta 30 días después de la última dosis del fármaco del estudio o del inicio de un nuevo tratamiento antineoplásico, lo que ocurra primero. |
|
E.5.2 | Secondary end point(s) |
- PFS per investigator assessment - DOR per investigator assessment - OS |
• SSP según la evaluación del investigador • DR según la evaluación del investigador • SG |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- the time from the starting date of zanubrutinib to the date of first documentation of PD or death, whichever occurs first - the time from the date that the response criteria are first met after the start of zanubrutinib to the date that PD is documented or death - the time from the starting date of zanubrutinib to the date of death due to any reason |
- el tiempo desde la fecha de inicio de zanubrutinib hasta la fecha de la primera documentación de EP o muerte, lo que ocurra primero - el tiempo desde la fecha en que se cumplen los criterios de respuesta por primera vez después del inicio de zanubrutinib hasta la fecha en que se documenta la EP o la muerte - el tiempo desde la fecha de inicio de zanubrutinib hasta la fecha de muerte por cualquier motivo |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 42 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
China |
Korea, Republic of |
New Zealand |
United States |
France |
Germany |
Italy |
Netherlands |
Poland |
Spain |
Sweden |
United Kingdom |
Czechia |
Greece |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |